Risultati per: Analisi sull’uso dei farmaci anti-osteoporotici in sette database europei

Fiaso presenta indagine Demopolis. Migliore, aiuto straordinario

Risultati positivi studio. Giù del 42% rischio morte a 39 mesi

Introduction
Polycystic ovary syndrome (PCOS), recognised as the predominant aetiological factor in ovulatory dysfunction-related infertility, accounts for approximately 70% of anovulatory infertility cases. Patients with PCOS have significantly higher anti-Müllerian hormone (AMH) levels than their counterparts undergoing in vitro fertilisation (IVF) for non-PCOS indications (eg, male/tubal factors). Several studies have suggested that a high AMH level is associated with adverse pregnancy outcomes in IVF, particularly preterm delivery. However, most of these studies are retrospective studies, and their results are inconsistent. The majority of AMH measurements are conducted before pregnancy; however, AMH levels fluctuate dynamically during pregnancy. There is a pressing need for a well-structured prospective study to definitively establish whether high AMH levels during pregnancy are associated with IVF/intracytoplasmic sperm injection (ICSI) pregnancy outcomes in PCOS patients.

Methods and analysis
This prospective cohort study will be conducted at four reproductive medicine centres. The plan is to enrol 1,320 PCOS patients and 1320 non-PCOS women who undergo IVF/ICSI and achieve singleton clinical pregnancies. Serum samples will be collected at about 6 weeks of gestation to measure the serum AMH level. Follow-up visits will be conducted at 12, 28 and 37 weeks of gestation, delivery and 6 weeks after delivery to obtain information about pregnancy outcomes and complications. The primary outcome is preterm delivery.

Ethics and dissemination
The study was approved by the Medical Research Ethics Committee of Peking University Third Hospital (M2022618). Informed consent will be obtained from all patients. The results of this clinical study will be presented at scientific conferences and submitted to a peer-reviewed journal.

Trial registration number
ChiCTR2300068554.

In un terzo dei pazienti malattia regredita completamente

H. pylori infection may represent a significant risk factor for the development of colorectal cancer. The effect of anti-H. pylori treatment on colorectal cancer incidence and mortality necessitates further investigation through large-scale, randomized controlled trials with prolonged follow-up durations.

La nuova normativa Ue, si passa da consenso a opt-out

Il pacchetto farmaceutico Ue approda alla fase finale

Andos, a carico delle pazienti. Tossicità finanziaria per il 38%

Dati positivi da studio che combina zanubrutinib e venetoclax

Mostrata l’efficacia in alcuni studi, cala il ischio di morte e di progressione della malattia

Dati positivi da studio che combina zanubrutinib e venetoclax

Dati positivi da studio che combina zanubrutinib e venetoclax

Mostrata efficacia in studi, giù rischio di morte e progressione

Mostrata efficacia in studi, giù rischio di morte e progressione

Mostrata efficacia in studi, giù rischio di morte e progressione

In un anno +9,6%. Oncologi,’va governata’. Morti in calo del 15%